Novavax, Inc.
NVAX
$10.74
$0.666.55%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 108.87% | -70.55% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 108.87% | -70.55% | |||
| Cost of Revenue | 17.54% | 29.15% | |||
| Gross Profit | 175.91% | -120.92% | |||
| SG&A Expenses | -121.16% | -13.43% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.77% | 12.17% | |||
| Operating Income | 126.38% | -175.12% | |||
| Income Before Tax | 108.82% | -288.95% | |||
| Income Tax Expenses | 157.23% | -169.45% | |||
| Earnings from Continuing Operations | 108.66% | -290.01% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 108.66% | -290.01% | |||
| EBIT | 126.38% | -175.12% | |||
| EBITDA | 135.80% | -164.29% | |||
| EPS Basic | 108.65% | -289.61% | |||
| Normalized Basic EPS | 132.46% | -170.44% | |||
| EPS Diluted | 108.62% | -302.96% | |||
| Normalized Diluted EPS | 131.95% | -177.03% | |||
| Average Basic Shares Outstanding | 0.11% | 0.21% | |||
| Average Diluted Shares Outstanding | 1.74% | -8.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||